Skip to main content
SpringerLink
Log in

Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance

  • Chapter
  • First Online:
Resistance to Targeted ABC Transporters in Cancer

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics ((RTACT,volume 4))

Abstract

The breast cancer resistance protein (BCRP), formally known as ATP-binding cassette protein G2 (ABCG2), is an efflux transporter that plays a significant role in altering absorption, distribution, metabolism, and excretion (ADME) of most extant and emerging molecular cancer therapeutics. BCRP expressed by neoplastic cells may also contribute to the resistance of these cells to chemotherapeutic agents. Although the expression of BCRP in human cancers has often correlated with adverse outcomes, to date therapeutic strategies utilizing the inhibition of BCRP function to improve the ADME of cancer chemotherapeutics or to sensitize cancer cells that express BCRP to chemotherapy have not been fruitful. This review will examine the most current literature probing BCRP’s role in ADME of cancer therapeutic agents and drug resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ABCG2:

ATP-binding cassette protein G2

ADME:

Absorption, distribution, metabolism, and elimination

BCRP:

Breast cancer resistance protein

MDR:

Multidrug resistance

References

  1. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95:15665–70.

    PubMed Central  CAS  PubMed  Google Scholar 

  2. Ross DD, Nakanishi T. Impact of breast cancer resistance protein on cancer treatment outcomes. In: Zhou J, editor. Methods in molecular biology, vol. 596. New York, NY: Humana, Springer; 2010. p. 251–90.

    Google Scholar 

  3. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 2012;83:1084–103.

    PubMed Central  CAS  PubMed  Google Scholar 

  4. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 2001;61:6635–9.

    CAS  PubMed  Google Scholar 

  5. Allen JD, Jackson SC, Schinkel AH. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res. 2002;62:2294–9.

    CAS  PubMed  Google Scholar 

  6. Ni Z, Bikadi Z, Shuster DL, Zhao C, Rosenberg MF, Mao Q. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity. Biochemistry. 2011;50:8057–66.

    PubMed Central  CAS  PubMed  Google Scholar 

  7. Velamakanni S, Janvilisri T, Shahi S, van Veen HW. A functional steroid-binding element in an ATP-binding cassette multidrug transporter. Mol Pharmacol. 2008;73:12–7.

    CAS  PubMed  Google Scholar 

  8. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003;278:22644–9.

    CAS  PubMed  Google Scholar 

  9. Vaidya SS, Gerk PM. Lack of interaction between tauroursodeoxycholate and ATP-binding cassette transporter isoform G2 (ABCG2). Mol Pharm. 2006;3:303–6.

    CAS  PubMed  Google Scholar 

  10. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003;64:610–8.

    CAS  PubMed  Google Scholar 

  11. Janvilisri T, Shahi S, Venter H, Balakrishnan L, van Veen HW. Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005;385:419–26.

    PubMed Central  CAS  PubMed  Google Scholar 

  12. Telbisz A, Ozvegy-Laczka C, Hegedus T, Varadi A, Sarkadi B. Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein. Biochem J. 2013;450:387–95.

    CAS  PubMed  Google Scholar 

  13. Dankers AC, Sweep FC, Pertijs JC, Verweij V, van den Heuvel JJ, Koenderink JB, Russel FG, Masereeuw R. Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012;349:551–63.

    PubMed Central  CAS  PubMed  Google Scholar 

  14. Kobuchi H, Moriya K, Ogino T, Fujita H, Inoue K, Shuin T, Yasuda T, Utsumi K, Utsumi T. Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation. PLoS One. 2012;7:e50082.

    PubMed Central  CAS  PubMed  Google Scholar 

  15. Lin YH, Chang HM, Chang FP, Shen CR, Liu CL, Mao WY, Lin CC, Lee HS, Shen CN. Protoporphyrin IX accumulation disrupts mitochondrial dynamics and function in ABCG2-deficient hepatocytes. FEBS Lett. 2013;587:3202–9.

    CAS  PubMed  Google Scholar 

  16. Bhatia P, Bernier M, Sanghvi M, Moaddel R, Schwarting R, Ramamoorthy A, Wainer IW. Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells. Xenobiotica. 2012;42:748–55.

    PubMed Central  CAS  PubMed  Google Scholar 

  17. Zhao S, Chen C, Liu S, Zeng W, Su J, Wu L, Luo Z, Zhou S, Li Q, Zhang J, Kuang Y, Chen X. CD147 promotes MTX resistance by immune cells through up-regulating ABCG2 expression and function. J Dermatol Sci. 2013;70:182–9.

    CAS  PubMed  Google Scholar 

  18. Qian X, Cheng YH, Mruk DD, Cheng CY. Breast cancer resistance protein (Bcrp) and the testis-an unexpected turn of events. Asian J Androl. 2013;15:455–60.

    PubMed Central  CAS  PubMed  Google Scholar 

  19. Qian X, Mruk DD, Wong EW, Cheng CY. Breast cancer resistance protein regulates apical ectoplasmic specialization dynamics stage specifically in the rat testis. Am J Physiol Endocrinol Metab. 2013;304:E757–69.

    PubMed Central  CAS  PubMed  Google Scholar 

  20. Sereti KI, Oikonomopoulos A, Unno K, Cao X, Qiu Y, Liao R. ATP-binding cassette G-subfamily transporter 2 regulates cell cycle progression and asymmetric division in mouse cardiac side population progenitor cells. Circ Res. 2013;112:27–34.

    PubMed Central  CAS  PubMed  Google Scholar 

  21. Scharenberg C, Mannowetz N, Robey RW, Brendel C, Repges P, Sahrhage T, Jahn T, Wennemuth G. ABCG2 is expressed in late spermatogenesis and is associated with the acrosome. Biochem Biophys Res Commun. 2009;378:302–7.

    CAS  PubMed  Google Scholar 

  22. Cooray HC, Blackmore CG, Maskell L, Barrand MA. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport. 2002;13:2059–63.

    CAS  PubMed  Google Scholar 

  23. Yasuda K, Cline C, Vogel P, Onciu M, Fatima S, Sorrentino BP, Thirumaran RK, Ekins S, Urade Y, Fujimori K, Schuetz EG. Drug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier. Drug Metab Dispos. 2013;41:923–31.

    PubMed Central  CAS  PubMed  Google Scholar 

  24. Memon N, Bircsak KM, Archer F, Gibson CJ, Ohman-Strickland P, Weinberger BI, Parast MM, Vetrano AM, Aleksunes LM. Regional expression of the BCRP/ABCG2 transporter in term human placentas. Reprod Toxicol. 2014;43:72–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  25. Dahlin A, Geier E, Stocker SL, Cropp CD, Grigorenko E, Bloomer M, Siegenthaler J, Xu L, Basile AS, Tang-Liu DD, Giacomini KM. Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. Mol Pharm. 2013;10:650–63.

    PubMed Central  CAS  PubMed  Google Scholar 

  26. Martin V, Sanchez-Sanchez AM, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega MA, Antolin I, Rodriguez C. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer. 2013;108:2005–12.

    PubMed Central  CAS  PubMed  Google Scholar 

  27. Nakanishi T, Bailey-Dell KJ, Hassel BA, Shiozawa K, Sullivan DM, Turner J, Ross DD. Novel 5′ untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. Cancer Res. 2006;66:5007–11.

    CAS  PubMed  Google Scholar 

  28. Natarajan K, Xie Y, Nakanishi T, Beck WT, Bauer KS, Ross DD. Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine. Biochim Biophys Acta. 2011;1809:295–305.

    PubMed Central  CAS  PubMed  Google Scholar 

  29. Zong Y, Zhou S, Fatima S, Sorrentino BP. Expression of mouse Abcg2 mRNA during hematopoiesis is regulated by alternative use of multiple leader exons and promoters. J Biol Chem. 2006;281:29625–32.

    CAS  PubMed  Google Scholar 

  30. Campbell PK, Zong Y, Yang S, Zhou S, Rubnitz JE, Sorrentino BP. Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. Leuk Res. 2011;35:1321–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  31. Xie Y, Natarajan K, Bauer KS, Nakanishi T, Beck WT, Moreci RS, Jeyasuria P, Hussain A, Ross DD. Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1. Biochim Biophys Acta. 2013;1829:1288–99.

    CAS  PubMed  Google Scholar 

  32. de Boussac H, Orban TI, Varady G, Tihanyi B, Bacquet C, Brozik A, Varadi A, Sarkadi B, Aranyi T. Stimulus-induced expression of the ABCG2 multidrug transporter in HepG2 hepatocarcinoma model cells involves the ERK1/2 cascade and alternative promoters. Biochem Biophys Res Commun. 2012;426:172–6.

    PubMed  Google Scholar 

  33. Tompkins LM, Li H, Li L, Lynch C, Xie Y, Nakanishi T, Ross DD, Wang H. A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. Biochem Pharmacol. 2010;80:1754–61.

    PubMed Central  CAS  PubMed  Google Scholar 

  34. Tan KP, Wang B, Yang M, Boutros PC, Macaulay J, Xu H, Chuang AI, Kosuge K, Yamamoto M, Takahashi S, Wu AM, Ross DD, Harper PA, Ito S. Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2). Mol Pharmacol. 2010;78:175–85.

    CAS  PubMed  Google Scholar 

  35. Yang WJ, Song MJ, Park EY, Lee JJ, Park JH, Park K, Park JH, Kim HP. Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype. Mol Cells. 2013;36:368–75.

    PubMed Central  CAS  PubMed  Google Scholar 

  36. Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res. 2004;64:1247–51.

    CAS  PubMed  Google Scholar 

  37. Li W, Jia M, Qin X, Hu J, Zhang X, Zhou G. Harmful effect of ERbeta on BCRP-mediated drug resistance and cell proliferation in ERalpha/PR-negative breast cancer. FEBS J. 2013;280:6128–40.

    CAS  PubMed  Google Scholar 

  38. Wu AM, Dalvi P, Lu X, Yang M, Riddick DS, Matthews J, Clevenger CV, Ross DD, Harper PA, Ito S. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. Mol Pharmacol. 2013;83:377–88.

    CAS  PubMed  Google Scholar 

  39. Rosenfeldt MT, Bell LA, Long JS, O’Prey J, Nixon C, Roberts F, Dufes C, Ryan KM. E2F1 drives chemotherapeutic drug resistance via ABCG2. Oncogene. 2013;33:4164–72.

    PubMed  Google Scholar 

  40. To KK, Yu L, Liu S, Fu J, Cho CH. Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells. Mol Carcinog. 2012;51:449–64.

    CAS  PubMed  Google Scholar 

  41. An Y, Kiang A, Lopez JP, Kuo SZ, Yu MA, Abhold EL, Chen JS, Wang-Rodriguez J, Ongkeko WM. Cigarette smoke promotes drug resistance and expansion of cancer stem cell-like side population. PLoS One. 2012;7:e47919.

    PubMed Central  CAS  PubMed  Google Scholar 

  42. Zhang M, Mathur A, Zhang Y, Xi S, Atay S, Hong JA, Datrice N, Upham T, Kemp CD, Ripley RT, Wiegand G, Avital I, Fetsch P, Mani H, Zlott D, Robey R, Bates SE, Li X, Rao M, Schrump DS. Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells. Cancer Res. 2012;72:4178–92.

    CAS  PubMed  Google Scholar 

  43. Benoki S, Yoshinari K, Chikada T, Imai J, Yamazoe Y. Transactivation of ABCG2 through a novel cis-element in the distal promoter by constitutive androstane receptor but not pregnane X receptor in human hepatocytes. Arch Biochem Biophys. 2012;517:123–30.

    CAS  PubMed  Google Scholar 

  44. Lemmen J, Tozakidis IE, Bele P, Galla HJ. Constitutive androstane receptor upregulates Abcb1 and Abcg2 at the blood–brain barrier after CITCO activation. Brain Res. 2013;1501:68–80.

    CAS  PubMed  Google Scholar 

  45. Hoque MT, Robillard KR, Bendayan R. Regulation of breast cancer resistant protein by peroxisome proliferator-activated receptor alpha in human brain microvessel endothelial cells. Mol Pharmacol. 2012;81:598–609.

    CAS  PubMed  Google Scholar 

  46. Eldasher LM, Wen X, Little MS, Bircsak KM, Yacovino LL, Aleksunes LM. Hepatic and renal Bcrp transporter expression in mice treated with perfluorooctanoic acid. Toxicology. 2013;306:108–13.

    PubMed Central  CAS  PubMed  Google Scholar 

  47. Hamdan AM, Koyanagi S, Wada E, Kusunose N, Murakami Y, Matsunaga N, Ohdo S. Intestinal expression of mouse Abcg2/breast cancer resistance protein (BCRP) gene is under control of circadian clock-activating transcription factor-4 pathway. J Biol Chem. 2012;287:17224–31.

    PubMed Central  CAS  PubMed  Google Scholar 

  48. Samanta S, Pursell B, Mercurio AM. IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression. J Biol Chem. 2013;288:12569–73.

    PubMed Central  CAS  PubMed  Google Scholar 

  49. Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai XF, Yu ZJ, Wu HZ, Sun ML, Song ZG, Wei MJ. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett. 2013;339: 107–15.

    CAS  PubMed  Google Scholar 

  50. Shen WW, Zeng Z, Zhu WX, Fu GH. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med. 2013;91:989–1000.

    CAS  PubMed  Google Scholar 

  51. Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y, Wang Y, Chen Q, Zhao X, Zhou M, Cui Z, Zheng Z, Wang E, Wei M. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat. 2013;139:717–30.

    CAS  PubMed  Google Scholar 

  52. To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther. 2009;8: 2959–68.

    PubMed Central  CAS  PubMed  Google Scholar 

  53. Wang F, Xue X, Wei J, An Y, Yao J, Cai H, Wu J, Dai C, Qian Z, Xu Z, Miao Y. hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br J Cancer. 2010;103:567–74.

    PubMed Central  CAS  PubMed  Google Scholar 

  54. Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012; 279:2047–59.

    CAS  PubMed  Google Scholar 

  55. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol. 2009;75:1374–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  56. Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics. 2012;22:198–205.

    CAS  PubMed  Google Scholar 

  57. Koshkin PA, Chistiakov DA, Nikitin AG, Konovalov AN, Potapov AA, Usachev DY, Pitskhelauri DI, Kobyakov GL, Shishkina LV, Chekhonin VP. Analysis of expression of microRNAs and genes involved in the control of key signaling mechanisms that support or inhibit development of brain tumors of different grades. Clin Chim Acta. 2014;430:55–62.

    CAS  PubMed  Google Scholar 

  58. Diop NK, Hrycyna CA. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry. 2005;44:5420–9.

    CAS  PubMed  Google Scholar 

  59. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, Sugimoto Y. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer. 2002;97:626–30.

    CAS  PubMed  Google Scholar 

  60. Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD. Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol. 2003;64:1452–62.

    CAS  PubMed  Google Scholar 

  61. Xu J, Liu Y, Yang Y, Bates S, Zhang JT. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem. 2004;279:19781–9.

    CAS  PubMed  Google Scholar 

  62. Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, Gleave ME, Qiu Y. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2008;283:3349–56.

    CAS  PubMed  Google Scholar 

  63. Natarajan K, Bhullar J, Shukla S, Burcu M, Chen ZS, Ambudkar SV, Baer MR. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochem Pharmacol. 2013;85:514–24.

    CAS  PubMed  Google Scholar 

  64. Mogi M, Yang J, Lambert JF, Colvin GA, Shiojima I, Skurk C, Summer R, Fine A, Quesenberry PJ, Walsh K. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem. 2003;278:39068–75.

    CAS  PubMed  Google Scholar 

  65. Takada T, Suzuki H, Gotoh Y, Sugiyama Y. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab Dispos. 2005;33:905–9.

    CAS  PubMed  Google Scholar 

  66. Xu JW, Li QQ, Tao LL, Cheng YY, Yu J, Chen Q, Liu XP, Xu ZD. Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells. Int J Oncol. 2011;39:1501–9.

    PubMed  Google Scholar 

  67. Pick A, Wiese M. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway. ChemMedChem. 2012;7:650–62.

    CAS  PubMed  Google Scholar 

  68. To KK, Tomlinson B. Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARgamma agonists. Br J Pharmacol. 2013;170:1137–51.

    PubMed Central  CAS  PubMed  Google Scholar 

  69. Lin F, Yan W, Wen T, Wu GY. [Metformin induces apoptosis in hepatocellular carcinoma Huh-7 cells in vitro and its mechanism]. Zhonghua Zhong Liu Za Zhi. 2013;35:742–6.

    CAS  PubMed  Google Scholar 

  70. Tomiyasu H, Watanabe M, Sugita K, Goto-Koshino Y, Fujino Y, Ohno K, Sugano S, Tsujimoto H. Regulations of ABCB1 and ABCG2 expression through MAPK pathways in acute lymphoblastic leukemia cell lines. Anticancer Res. 2013;33:5317–23.

    CAS  PubMed  Google Scholar 

  71. Zhu MM, Tong JL, Xu Q, Nie F, Xu XT, Xiao SD, Ran ZH. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer. PLoS One. 2012;7:e41763.

    PubMed Central  CAS  PubMed  Google Scholar 

  72. Chau WK, Ip CK, Mak AS, Lai HC, Wong AS. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene. 2013;32:2767–81.

    CAS  PubMed  Google Scholar 

  73. Latorre E, Castiglioni I, Gatto P, Carelli S, Quattrone A, Provenzani A. Loss of protein kinase Cdelta/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines. J Pharmacol Exp Ther. 2014;349:99–106.

    PubMed  Google Scholar 

  74. Oda K, Nishimura T, Higuchi K, Ishido N, Ochi K, Iizasa H, Sai Y, Tomi M, Nakashima E. Estrogen receptor alpha induction by mitoxantrone increases Abcg2 expression in placental trophoblast cells. J Pharm Sci. 2013;102:3364–72.

    CAS  PubMed  Google Scholar 

  75. Ke SZ, Ni XY, Zhang YH, Wang YN, Wu B, Gao FG. Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-kappaB pathway in lung cancer cells. Int J Oncol. 2013;42:1289–96.

    CAS  PubMed  Google Scholar 

  76. Wei Y, Ma Y, Zhao Q, Ren Z, Li Y, Hou T, Peng H. New use for an old drug: inhibiting ABCG2 with sorafenib. Mol Cancer Ther. 2012;11:1693–702.

    CAS  PubMed  Google Scholar 

  77. To KK, Ren SX, Wong CC, Cho CH. Reversal of ABCG2-mediated multidrug resistance by human cathelicidin and its analogs in cancer cells. Peptides. 2013;40:13–21.

    CAS  PubMed  Google Scholar 

  78. Niu Q, Wang W, Li Y, Ruden DM, Wang F, Song J, Zheng K. Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation. PLoS One. 2012;7:e41035.

    PubMed Central  CAS  PubMed  Google Scholar 

  79. Hu YP, Tao LY, Wang F, Zhang JY, Liang YJ, Fu LW. Secalonic acid D reduced the percentage of side populations by down-regulating the expression of ABCG2. Biochem Pharmacol. 2013;85:1619–25.

    CAS  PubMed  Google Scholar 

  80. Giacomini KM, Balimane PV, Cho SK, Eadon M, Edeki T, Hillgren KM, Huang SM, Sugiyama Y, Weitz D, Wen Y, Xia CQ, Yee SW, Zimdahl H, Niemi M, International Transporter C. International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin Pharmacol Ther. 2013;94:23–6.

    CAS  PubMed  Google Scholar 

  81. Chen P, Zhao L, Zou P, Xu H, Lu A, Zhao P. The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature. BMC Cancer. 2012;12:383.

    PubMed Central  PubMed  Google Scholar 

  82. Basseville A, Tamaki A, Ierano C, Trostel S, Ward Y, Robey RW, Hegde RS, Bates SE. Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter. Cancer Res. 2012;72:3642–51.

    PubMed Central  CAS  PubMed  Google Scholar 

  83. Saranko H, Tordai H, Telbisz A, Ozvegy-Laczka C, Erdos G, Sarkadi B, Hegedus T. Effects of the gout-causing Q141K polymorphism and a CFTR DeltaF508 mimicking mutation on the processing and stability of the ABCG2 protein. Biochem Biophys Res Commun. 2013;437:140–5.

    CAS  PubMed  Google Scholar 

  84. Woodward OM, Köttgen A, Coresh J, Boerwinkle E, Guggino WB, Köttgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009;106:10338–42.

    PubMed Central  CAS  PubMed  Google Scholar 

  85. Prasad B, Lai Y, Lin Y, Unadkat JD. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. J Pharm Sci. 2013;102:787–93.

    CAS  PubMed  Google Scholar 

  86. de Lima LT, Vivona D, Bueno CT, Hirata RD, Hirata MH, Luchessi AD, de Castro FA, de Lourdes FCM, Zanichelli MA, Chiattone CS, Hungria VT, Guerra-Shinohara EM. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Med Oncol. 2014;31:851.

    PubMed  Google Scholar 

  87. Au A, Aziz Baba A, Goh AS, Wahid Fadilah SA, Teh A, Rosline H, Ankathil R. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomed Pharmacother. 2014;68:343–9.

    CAS  PubMed  Google Scholar 

  88. Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol. 2013;24:756–60.

    CAS  PubMed  Google Scholar 

  89. Shinohara Y, Takahashi N, Nishiwaki K, Hino M, Kashimura M, Wakita H, Hatano Y, Hirasawa A, Nakagawa Y, Itoh K, Masuoka H, Aotsuka N, Matsuura Y, Takahara S, Sano K, Kuroki J, Hata T, Nakamae H, Mugitani A, Nakane T, Miyazaki Y, Niioka T, Miura M, Sawada K. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. Haematologica. 2013;98:1407–13.

    PubMed Central  CAS  PubMed  Google Scholar 

  90. Delord M, Rousselot P, Cayuela JM, Sigaux F, Guilhot J, Preudhomme C, Guilhot F, Loiseau P, Raffoux E, Geromin D, Genin E, Calvo F, Bruzzoni-Giovanelli H. High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget. 2013;4:1582–91.

    PubMed Central  PubMed  Google Scholar 

  91. Tiribelli M, Fabbro D, Franzoni A, Fanin R, Damante G, Damiani D. Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy. Haematologica. 2013;98:e28–9.

    PubMed Central  PubMed  Google Scholar 

  92. Wang F, Liang YJ, Wu XP, Chen LM, To KK, Dai CL, Yan YY, Wang YS, Tong XZ, Fu LW. Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia. Eur J Cancer. 2011;47:1990–9.

    CAS  PubMed  Google Scholar 

  93. Boso V, Herrero MJ, Buso E, Galan J, Almenar L, Sanchez-Lazaro I, Sanchez-Plumed J, Bea S, Prieto M, Garcia M, Pastor A, Sole A, Poveda JL, Alino SF. Genotype and allele frequencies of drug-metabolizing enzymes and drug transporter genes affecting immunosuppressants in the spanish white population. Ther Drug Monit. 2014;36:159–68.

    CAS  PubMed  Google Scholar 

  94. Campa D, Butterbach K, Slager SL, Skibola CF, de Sanjose S, Benavente Y, Becker N, Foretova L, Maynadie M, Cocco P, Staines A, Kaaks R, Boffetta P, Brennan P, Conde L, Bracci PM, Caporaso NE, Strom SS, Camp NJ, Cerhan JR, Consortium G, Canzian F, Nieters A. A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk. Int J Cancer. 2012;131:803–12.

    PubMed Central  CAS  PubMed  Google Scholar 

  95. Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, Higuera O, Burgos E, Ramos D, Calatrava A, Andrada E, Lopez R, Moreno V, Madero R, Cejas P, Feliu J. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol. 2014;25:398–403.

    CAS  PubMed  Google Scholar 

  96. Shaffer JR, Feingold E, Wang X, Lee M, Tcuenco K, Weeks DE, Weyant RJ, Crout R, McNeil DW, Marazita ML. GWAS of dental caries patterns in the permanent dentition. J Dent Res. 2013;92:38–44.

    PubMed Central  CAS  PubMed  Google Scholar 

  97. De Mattia E, Toffoli G, Polesel J, D’Andrea M, Corona G, Zagonel V, Buonadonna A, Dreussi E, Cecchin E. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet Genomics. 2013;23:549–57.

    PubMed  Google Scholar 

  98. Lin PC, Lin HH, Lin JK, Lin CC, Yang SH, Li AF, Chen WS, Chang SC. Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy–preliminary evidence. Int J Biol Markers. 2013;28:182–6.

    CAS  PubMed  Google Scholar 

  99. Zhao J, Li W, Zhu D, Yu Q, Zhang Z, Sun M, Cai S, Zhang W. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Med Oncol. 2014;31:802.

    PubMed Central  PubMed  Google Scholar 

  100. Tamura M, Kondo M, Horio M, Ando M, Saito H, Yamamoto M, Horio Y, Hasegawa Y. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. Nagoya J Med Sci. 2012;74:133–40.

    CAS  PubMed  Google Scholar 

  101. Kim SH, Kim MJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim IS, Lee S, Oh SY, Ling H, Lee GW. Clinical significance of ABCG2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy. Am J Clin Oncol. 2013 [Epub ahead of print].

    Google Scholar 

  102. Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, Mio T, Terada T, Teramukai S, Mishima M, Inui K, Katsura T. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet. 2013;52:593–609.

    CAS  PubMed  Google Scholar 

  103. Mizuno T, Fukudo M, Terada T, Kamba T, Nakamura E, Ogawa O, Inui K, Katsura T. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. Drug Metab Pharmacokinet. 2012;27:631–9.

    CAS  PubMed  Google Scholar 

  104. Kim HR, Park HS, Kwon WS, Lee JH, Tanigawara Y, Lim SM, Kim HS, Shin SJ, Ahn JB, Rha SY. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol. 2013;72:825–35.

    CAS  PubMed  Google Scholar 

  105. Awada Z, Haider S, Tfayli A, Bazarbachi A, El-Saghir NS, Salem Z, Shamseddine A, Taher A, Zgheib NK. Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013;17:353–67.

    CAS  PubMed  Google Scholar 

  106. Agarwal S, Elmquist WF. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood–brain barrier: a case study examining sorafenib efflux clearance. Mol Pharm. 2012;9:678–84.

    PubMed Central  PubMed  Google Scholar 

  107. de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs. 2010;30:443–9.

    PubMed  Google Scholar 

  108. Sane R, Wu SP, Zhang R, Gallo JM. The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain. Drug Metab Dispos. 2014;42:537–40.

    PubMed Central  PubMed  Google Scholar 

  109. Xiao G, Black C, Hetu G, Sands E, Wang J, Caputo R, Rohde E, Gan LS. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates. Drug Metab Dispos. 2012;40:779–87.

    CAS  PubMed  Google Scholar 

  110. Durmus S, Xu N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. Pharmacol Res. 2013;76:9–16.

    CAS  PubMed  Google Scholar 

  111. Tang SC, de Vries N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib. J Pharmacol Exp Ther. 2013;346:486–94.

    CAS  PubMed  Google Scholar 

  112. Yano H, Tamura Y, Kobayashi K, Tanemoto M, Uchida S. Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease. Clin Exp Nephrol. 2014;18:50–5.

    CAS  PubMed  Google Scholar 

  113. Zander SA, Sol W, Greenberger L, Zhang Y, van Tellingen O, Jonkers J, Borst P, Rottenberg S. EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One. 2012;7:e45248.

    PubMed Central  CAS  PubMed  Google Scholar 

  114. Zhang P, Ling G, Pan X, Sun J, Zhang T, Pu X, Yin S, He Z. Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride. Nanomedicine. 2012;8:185–93.

    PubMed  Google Scholar 

  115. Yang C, Xiong F, Wang J, Dou J, Chen J, Chen D, Zhang Y, Luo S, Gu N. Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma. Nanomedicine (Lond). 2014;9:45–60.

    CAS  Google Scholar 

  116. Sane R, Mittapalli RK, Elmquist WF. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J Pharm Sci. 2013;102:1343–54.

    PubMed Central  CAS  PubMed  Google Scholar 

  117. Li YT, Chua MJ, Kunnath AP, Chowdhury EH. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs. Int J Nanomedicine. 2012;7:2473–81.

    PubMed Central  CAS  PubMed  Google Scholar 

  118. Aliabadi HM, Landry B, Mahdipoor P, Hsu CY, Uludag H. Effective down-regulation of breast cancer resistance protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers. Eur J Pharm Biopharm. 2012;81:33–42.

    CAS  PubMed  Google Scholar 

  119. Huang FF, Wu DS, Zhang L, Yu YH, Yuan XY, Li WJ, Chen XP, Zhao XL, Chen FP, Zeng H. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett. 2013;336:96–105.

    CAS  PubMed  Google Scholar 

  120. Huang FF, Zhang L, Wu DS, Yuan XY, Chen FP, Zeng H, Yu YH, Zhao XL. PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia. PLoS One. 2014;9:e88298.

    PubMed Central  PubMed  Google Scholar 

  121. Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, Terragna C, Durante S, Valli E, Kalebic T, Bernardoni R, Perrod C, Haber M, Norris MD, Baccarani M, Martinelli G, Perini G. c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells. Mol Cancer Res. 2011;9:1054–66.

    CAS  PubMed  Google Scholar 

  122. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, Vega F. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene. 2011;30:4874–86.

    PubMed Central  CAS  PubMed  Google Scholar 

  123. Qin Z, Dai L, Bratoeva M, Slomiany MG, Toole BP, Parsons C. Cooperative roles for emmprin and LYVE-1 in the regulation of chemoresistance for primary effusion lymphoma. Leukemia. 2011;25:1598–609.

    PubMed Central  CAS  PubMed  Google Scholar 

  124. Brozik A, Hegedus C, Erdei Z, Hegedus T, Ozvegy-Laczka C, Szakacs G, Sarkadi B. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol. 2011;7:623–42.

    CAS  PubMed  Google Scholar 

  125. Shukla S, Chen ZS, Ambudkar SV. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist Updat. 2012;15:70–80.

    PubMed Central  CAS  PubMed  Google Scholar 

  126. Eadie LN, Hughes TP, White DL. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clin Pharmacol Ther. 2014;95:294–306.

    CAS  PubMed  Google Scholar 

  127. Glodkowska-Mrowka E, Mrowka P, Basak GW, Niesiobedzka-Krezel J, Seferynska I, Wlodarski PK, Jakobisiak M, Stoklosa T. Statins inhibit ABCB1 and ABCG2 drug transporters activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib. Exp Hematol. 2014;42:439–47.

    CAS  PubMed  Google Scholar 

  128. Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther. 2012;341:164–73.

    CAS  PubMed  Google Scholar 

  129. Zhao XQ, Dai CL, Ohnuma S, Liang YJ, Deng W, Chen JJ, Zeng MS, Ambudkar SV, Chen ZS, Fu LW. Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2. Eur J Pharm Sci. 2013;49:441–50.

    CAS  PubMed  Google Scholar 

  130. Bhullar J, Natarajan K, Shukla S, Mathias TJ, Sadowska M, Ambudkar SV, Baer MR. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. PLoS One. 2013;8:e71266.

    PubMed Central  CAS  PubMed  Google Scholar 

  131. Wu CP, Hsiao SH, Sim HM, Luo SY, Tuo WC, Cheng HW, Li YQ, Huang YH, Ambudkar SV. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1. Biochem Pharmacol. 2013;86:904–13.

    PubMed Central  CAS  PubMed  Google Scholar 

  132. Grundy M, Seedhouse C, Russell NH, Pallis M. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. BMC Cancer. 2011;11:254.

    PubMed Central  CAS  PubMed  Google Scholar 

  133. Skoglund K, Boiso Moreno S, Jonsson JI, Vikingsson S, Carlsson B, Green H. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line. Pharmacogenet Genomics. 2014;24:52–61.

    CAS  PubMed  Google Scholar 

  134. Ishikawa T, Aw W, Kaneko K. Metabolic interactions of purine derivatives with human ABC transporter ABCG2: genetic testing to assess gout risk. Pharmaceuticals (Basel). 2013;6:1347–60.

    Google Scholar 

  135. Xu XT, Xu Q, Tong JL, Zhu MM, Nie F, Chen X, Xiao SD, Ran ZH. MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer. 2012;106:1320–30.

    PubMed Central  CAS  PubMed  Google Scholar 

  136. Patel VB, Yu Y, Das JK, Patel BB, Majumdar AP. Schlafen-3: a novel regulator of intestinal differentiation. Biochem Biophys Res Commun. 2009;388:752–6.

    PubMed Central  CAS  PubMed  Google Scholar 

  137. Oh PS, Patel VB, Sanders MA, Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP. Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G347–55.

    PubMed Central  CAS  PubMed  Google Scholar 

  138. Goncalves P, Gregorio I, Martel F. The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein. Am J Physiol Cell Physiol. 2011;301:C984–94.

    CAS  PubMed  Google Scholar 

  139. Dietrich CG, Vehr AK, Martin IV, Gassler N, Rath T, Roeb E, Schmitt J, Trautwein C, Geier A. Downregulation of breast cancer resistance protein in colon adenomas reduces cellular xenobiotic resistance and leads to accumulation of a food-derived carcinogen. Int J Cancer. 2011;129:546–52.

    CAS  PubMed  Google Scholar 

  140. Jiang Y, He Y, Li H, Li HN, Zhang L, Hu W, Sun YM, Chen FL, Jin XM. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Gastric Cancer. 2012;15:440–50.

    CAS  PubMed  Google Scholar 

  141. Hang D, Dong HC, Ning T, Dong B, Hou DL, Xu WG. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma. Dis Esophagus. 2012;25:638–44.

    CAS  PubMed  Google Scholar 

  142. Mohelnikova-Duchonova B, Brynychova V, Oliverius M, Honsova E, Kala Z, Muckova K, Soucek P. Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. Pancreas. 2013;42:707–16.

    CAS  PubMed  Google Scholar 

  143. Huang FT, Zhuan-Sun YX, Zhuang YY, Wei SL, Tang J, Chen WB, Zhang SN. Inhibition of hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance. Int J Oncol. 2012;41:1707–14.

    CAS  PubMed  Google Scholar 

  144. Lee SH, Kim H, Hwang JH, Lee HS, Cho JY, Yoon YS, Han HS. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients. Pathol Int. 2012;62:167–75.

    PubMed  Google Scholar 

  145. Vizio B, Mauri FA, Prati A, Trivedi P, Giacobino A, Novarino A, Satolli MA, Ciuffreda L, Camandona M, Gasparri G, Bellone G. Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma. Oncol Rep. 2012;27:69–76.

    PubMed  Google Scholar 

  146. Zeng H, Yu H, Lu L, Jain D, Kidd MS, Saif MW, Chanock SJ, Hartge P, Risch HA. Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. Pancreas. 2011;40:657–63.

    PubMed Central  PubMed  Google Scholar 

  147. Hamada S, Satoh K, Hirota M, Kanno A, Umino J, Ito H, Masamune A, Kikuta K, Kume K, Shimosegawa T. The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2. J Cell Physiol. 2012;227:729–38.

    CAS  PubMed  Google Scholar 

  148. Lu P, Sun H, Zhang L, Hou H, Zhang L, Zhao F, Ge C, Yao M, Wang T, Li J. Isocorydine targets the drug-resistant cellular side population through PDCD4-related apoptosis in hepatocellular carcinoma. Mol Med. 2012;18:1136–46.

    PubMed Central  CAS  PubMed  Google Scholar 

  149. Chen Q, Li W, Wan Y, Xia X, Wu Q, Chen Y, Lai Z, Yu C, Li W. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways. Hepatology. 2012;55:1820–9.

    CAS  PubMed  Google Scholar 

  150. Larbcharoensub N, Sornmayura P, Sirachainan E, Wilasrusmee C, Wanmoung H, Janvilisri T. Prognostic value of ABCG2 in moderately and poorly differentiated intrahepatic cholangiocarcinoma. Histopathology. 2011;59:235–46.

    PubMed  Google Scholar 

  151. Litviakov NV, Cherdyntseva NV, Tsyganov MM, Denisov EV, Garbukov EY, Merzliakova MK, Volkomorov VV, Vtorushin SV, Zavyalova MV, Slonimskaya EM, Perelmuter VM. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. Cancer Chemother Pharmacol. 2013;71:153–63.

    CAS  PubMed  Google Scholar 

  152. Britton KM, Eyre R, Harvey IJ, Stemke-Hale K, Browell D, Lennard TW, Meeson AP. Breast cancer, side population cells and ABCG2 expression. Cancer Lett. 2012;323:97–105.

    CAS  PubMed  Google Scholar 

  153. Wu X, Zhang X, Zhang H, Su P, Li W, Li L, Wang Y, Liu W, Gao P, Zhou G. Progesterone receptor downregulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer. Cancer Sci. 2012;103:959–67.

    CAS  PubMed  Google Scholar 

  154. Nakanishi T, Chumsri S, Khakpour N, Brodie AH, Leyland-Jones B, Hamburger AW, Ross DD, Burger AM. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer. 2010;102:815–26.

    PubMed Central  CAS  PubMed  Google Scholar 

  155. Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK, Brodie AH. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2012;135:681–92.

    CAS  PubMed  Google Scholar 

  156. Zhang W, Ding W, Chen Y, Feng M, Ouyang Y, Yu Y, He Z. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai). 2011;43:647–53.

    CAS  Google Scholar 

  157. Xiang L, Su P, Xia S, Liu Z, Wang Y, Gao P, Zhou G. ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma. Diagn Pathol. 2011;6:90.

    PubMed Central  PubMed  Google Scholar 

  158. Goler-Baron V, Assaraf YG. Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics. PLoS One. 2012;7:e35487.

    PubMed Central  CAS  PubMed  Google Scholar 

  159. Goler-Baron V, Sladkevich I, Assaraf YG. Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochem Pharmacol. 2012;83:1340–8.

    CAS  PubMed  Google Scholar 

  160. Xiang L, Liu ZH, Huan Q, Su P, Du GJ, Wang Y, Gao P, Zhou GY. Hypoxia-inducible factor-2a is associated with ABCG2 expression, histology-grade and Ki67 expression in breast invasive ductal carcinoma. Diagn Pathol. 2012;7:32.

    PubMed Central  PubMed  Google Scholar 

  161. Selever J, Gu G, Lewis MT, Beyer A, Herynk MH, Covington KR, Tsimelzon A, Dontu G, Provost P, Di Pietro A, Boumendjel A, Albain K, Miele L, Weiss H, Barone I, Ando S, Fuqua SA. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res. 2011;17:6510–21.

    PubMed Central  CAS  PubMed  Google Scholar 

  162. Rijavec M, Silar M, Triller N, Kern I, Cegovnik U, Kosnik M, Korosec P. Expressions of topoisomerase IIalpha and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients. Pathol Oncol Res. 2011;17:691–6.

    CAS  PubMed  Google Scholar 

  163. Minami T, Kijima T, Otani Y, Kohmo S, Takahashi R, Nagatomo I, Hirata H, Suzuki M, Inoue K, Takeda Y, Kida H, Tachibana I, Kumanogoh A. HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer. Mol Cancer Ther. 2012;11:830–41.

    CAS  PubMed  Google Scholar 

  164. Liu G, Cheng D, Ding K, Le Maitre A, Liu N, Patel D, Chen Z, Seymour L, Shepherd FA, Tsao MS. Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer. J Thorac Oncol. 2012;7:316–22.

    CAS  PubMed  Google Scholar 

  165. Gottschling S, Jensen K, Herth FJ, Thomas M, Schnabel PA, Herpel E. Lack of prognostic significance of neuroendocrine differentiation and stem cell antigen co-expression in resected early-stage non-small cell lung cancer. Anticancer Res. 2013;33:981–90.

    PubMed  Google Scholar 

  166. Herpel E, Jensen K, Muley T, Warth A, Schnabel PA, Meister M, Herth FJ, Dienemann H, Thomas M, Gottschling S. The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. Anticancer Res. 2011;31:4491–500.

    PubMed  Google Scholar 

  167. Merk J, Rolff J, Dorn C, Leschber G, Fichtner I. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur J Cardiothorac Surg. 2011;40:e29–33.

    PubMed  Google Scholar 

  168. Li F, Zeng H, Ying K. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol. 2011;28:1458–62.

    CAS  PubMed  Google Scholar 

  169. Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT, Lee YC, Lai TC, Lee CH, Hsiao YW, Lu J, Shen CN, Lu PJ, Hsiao M. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res. 2013;73:406–16.

    CAS  PubMed  Google Scholar 

  170. Shen B, Li D, Dong P, Gao S. Expression of ABC transporters is an unfavorable prognostic factor in laryngeal squamous cell carcinoma. Ann Otol Rhinol Laryngol. 2011;120:820–7.

    PubMed  Google Scholar 

  171. Feng JQ, Mi JG, Wu L, Ma LW, Shi LJ, Yang X, Liu W, Zhang CP, Zhou ZT. Expression of podoplanin and ABCG2 in oral erythroplakia correlate with oral cancer development. Oral Oncol. 2012;48:848–52.

    CAS  PubMed  Google Scholar 

  172. Liu W, Feng JQ, Shen XM, Wang HY, Liu Y, Zhou ZT. Two stem cell markers, ATP-binding cassette, G2 subfamily (ABCG2) and BMI-1, predict the transformation of oral leukoplakia to cancer: a long-term follow-up study. Cancer. 2012;118:1693–700.

    CAS  PubMed  Google Scholar 

  173. Zhang H, Liu W, Feng X, Wang L, Jiang X, Liu D, Zhang L, Zhu B, Zhou W, Jia W, Li G, Ren C. Identification of ABCG2(+) cells in nasopharyngeal carcinoma cells. Oncol Rep. 2012;27:1177–87.

    PubMed Central  CAS  PubMed  Google Scholar 

  174. DiNatale BC, Smith K, John K, Krishnegowda G, Amin SG, Perdew GH. Ah receptor antagonism represses head and neck tumor cell aggressive phenotype. Mol Cancer Res. 2012;10:1369–79.

    PubMed Central  CAS  PubMed  Google Scholar 

  175. Lheureux S, Krieger S, Weber B, Pautier P, Fabbro M, Selle F, Bourgeois H, Petit T, Lortholary A, Plantade A, Briand M, Leconte A, Richard N, Vilquin P, Clarisse B, Blanc-Fournier C, Joly F. Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial. Int J Gynecol Cancer. 2012;22:1483–8.

    PubMed  Google Scholar 

  176. Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore Jr DF, Keeney GL, Peethambaram PP, Haluska P. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2011;122:116–20.

    PubMed Central  CAS  PubMed  Google Scholar 

  177. Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H, DeLoia JA. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;124:575–81.

    PubMed Central  CAS  PubMed  Google Scholar 

  178. Adar Y, Stark M, Bram EE, Nowak-Sliwinska P, van den Bergh H, Szewczyk G, Sarna T, Skladanowski A, Griffioen AW, Assaraf YG. Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers. Cell Death Dis. 2012;3:e293.

    PubMed Central  CAS  PubMed  Google Scholar 

  179. Agarwal S, Mittapalli RK, Zellmer DM, Gallardo JL, Donelson R, Seiler C, Decker SA, Santacruz KS, Pokorny JL, Sarkaria JN, Elmquist WF, Ohlfest JR. Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther. 2012;11:2183–92.

    PubMed Central  CAS  PubMed  Google Scholar 

  180. Xu ZY, Wang K, Li XQ, Chen S, Deng JM, Cheng Y, Wang ZG. The ABCG2 transporter is a key molecular determinant of the efficacy of sonodynamic therapy with Photofrin in glioma stem-like cells. Ultrasonics. 2013;53:232–8.

    CAS  PubMed  Google Scholar 

  181. Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Santi S, Ferracini R, Maraldi NM. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol. 1995;68:226–39.

    CAS  PubMed  Google Scholar 

  182. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Giercksky KE, Nesland JM, Suo Z. Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines. Tumour Biol. 2012;33:967–78.

    PubMed Central  CAS  PubMed  Google Scholar 

  183. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T, Nesland JM, Suo Z. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One. 2011;6:e29170.

    PubMed Central  CAS  PubMed  Google Scholar 

  184. Fischer B, Frei C, Moura U, Stahel R, Felley-Bosco E. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy. Lung Cancer. 2012;78:23–9.

    PubMed  Google Scholar 

  185. Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM. A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest New Drugs. 2012;30:1660–70.

    PubMed Central  CAS  PubMed  Google Scholar 

  186. Martins-Neves SR, Lopes AO, do Carmo A, Paiva AA, Simoes PC, Abrunhosa AJ, Gomes CM. Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer. 2012;12:139.

    PubMed Central  CAS  PubMed  Google Scholar 

  187. Wu CP, Sim HM, Huang YH, Liu YC, Hsiao SH, Cheng HW, Li YQ, Ambudkar SV, Hsu SC. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem Pharmacol. 2013;85:325–34.

    PubMed Central  CAS  PubMed  Google Scholar 

  188. Sostelly A, Payen L, Guitton J, Di Pietro A, Falson P, et al. Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model. Fundam Clin Pharmacol. 2014;28:161–9.

    CAS  PubMed  Google Scholar 

  189. Lin F, de Gooijer MC, Moreno Roig E, Buil L, Christner SM, et al. ABCB1, ABCG2 and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin Cancer Res. 2014;20(10):2703–13.

    CAS  PubMed  Google Scholar 

  190. Chuan Tang S, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014;134:1484–94.

    CAS  PubMed  Google Scholar 

  191. Oberoi RK, Mittapalli RK, Elmquist WF. Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain. J Pharmacol Exp Ther. 2013;347:755–64.

    PubMed Central  CAS  PubMed  Google Scholar 

  192. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther. 2012;342:33–40.

    PubMed Central  CAS  PubMed  Google Scholar 

  193. Huang W, Wan C, Luo Q, Huang Z, Luo Q. Genistein-inhibited cancer stem cell-like properties and reduced chemoresistance of gastric cancer. Int J Mol Sci. 2014;15:3432–43.

    PubMed Central  CAS  PubMed  Google Scholar 

  194. Winter E, Devantier Neuenfeldt P, Chiaradia-Delatorre LD, Gauthier C, Yunes RA, et al. Symmetric bis-chalcones as a new type of Breast Cancer Resistance Protein inhibitors with a different mechanism than chromones. J Med Chem. 2014;57(7):2930–41.

    CAS  PubMed  Google Scholar 

  195. Valdameri G, Genoux-Bastide E, Gauthier C, Peres B, Terreux R, et al. 6-halogenochromones bearing tryptamine: one-step access to potent and highly selective inhibitors of breast cancer resistance protein. ChemMedChem. 2012;7:1177–80.

    CAS  PubMed  Google Scholar 

  196. Sodani K, Patel A, Anreddy N, Singh S, Yang DH, et al. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol. 2014;89(1):52–61.

    PubMed Central  CAS  PubMed  Google Scholar 

  197. Juvale K, Gallus J, Wiese M. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem. 2013;21:7858–73.

    CAS  PubMed  Google Scholar 

  198. Feinshtein V, Erez O, Ben-Zvi Z, Eshkoli T, Sheizaf B, et al. Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study. Am J Obstet Gynecol. 2013;209(573):e571–3, e515.

    Google Scholar 

  199. Tan KW, Killeen DP, Li Y, Paxton JW, Birch NP, et al. Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2). Eur J Pharmacol. 2014;723:346–52.

    CAS  PubMed  Google Scholar 

  200. Yamazaki R, Nishiyama Y, Furuta T, Hatano H, Igarashi Y, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011;10:1252–63.

    CAS  PubMed  Google Scholar 

  201. Shishido Y, Ueno S, Yamazaki R, Nagaoka M, Matsuzaki T. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. Anticancer Res. 2013;33:1379–86.

    CAS  PubMed  Google Scholar 

  202. Li XX, Dong Y, Wang W, Wang HL, Chen YY, et al. Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma. Stem Cells Dev. 2013;22:554–66.

    PubMed Central  CAS  PubMed  Google Scholar 

  203. Liao WY, Shen CN, Lin LH, Yang YL, Han HY, et al. Asperjinone, a nor-neolignan, and terrein, a suppressor of ABCG2-expressing breast cancer cells, from thermophilic Aspergillus terreus. J Nat Prod. 2012;75:630–5.

    CAS  PubMed  Google Scholar 

  204. Valdameri G, Pereira Rangel L, Spatafora C, Guitton J, Gauthier C, et al. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein. ACS Chem Biol. 2012;7:322–30.

    CAS  PubMed  Google Scholar 

  205. Sim HM, Wu CP, Ambudkar SV, Go ML. In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs. Biochem Pharmacol. 2011;82:1562–71.

    PubMed Central  CAS  PubMed  Google Scholar 

  206. Hofman J, Ahmadimoghaddam D, Hahnova L, Pavek P, Ceckova M, et al. Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Pharmacol Res. 2012;65:312–9.

    CAS  PubMed  Google Scholar 

  207. Hofman J, Kucera R, Cihalova D, Klimes J, Ceckova M, et al. Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1). PLoS One. 2013;8:e75520.

    PubMed Central  CAS  PubMed  Google Scholar 

  208. Cuestas ML, Sosnik A, Mathet VL. Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines. Mol Pharm. 2011;8:1152–64.

    CAS  PubMed  Google Scholar 

  209. Cuestas ML, Castillo AI, Sosnik A, Mathet VL. Downregulation of mdr1 and abcg2 genes is a mechanism of inhibition of efflux pumps mediated by polymeric amphiphiles. Bioorg Med Chem Lett. 2012;22:6577–9.

    CAS  PubMed  Google Scholar 

  210. Le Vee M, Jouan E, Stieger B, Lecureur V, Fardel O. Regulation of drug transporter expression by oncostatin M in human hepatocytes. Biochem Pharmacol. 2011;82:304–11.

    PubMed  Google Scholar 

  211. Sun W, Kajimoto Y, Inoue H, Miyatake S, Ishikawa T, et al. Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells. Photodiagnosis Photodyn Ther. 2013;10:42–50.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Greenebaum Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, MD, 20201, USA

    Karthika Natarajan Ph.D., Maria R. Baer M.D. & Douglas D. Ross M.D., Ph.D.

  2. The Baltimore VA Medical Center, 10 North Greene Street, Baltimore, MD, 21201, USA

    Douglas D. Ross M.D., Ph.D.

Authors
  1. Karthika Natarajan Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria R. Baer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas D. Ross M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas D. Ross M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Pharmaceutical Biology, Johannes Gutenberg University, Mainz, Germany

    Thomas Efferth

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Natarajan, K., Baer, M.R., Ross, D.D. (2015). Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance. In: Efferth, T. (eds) Resistance to Targeted ABC Transporters in Cancer. Resistance to Targeted Anti-Cancer Therapeutics, vol 4. Springer, Cham. https://doi.org/10.1007/978-3-319-09801-2_3

Download citation

Publish with us

Policies and ethics

Search

Navigation